News | Deal AnnouncementLeerink Partners Serves as Lead Placement Agent for Gossamer Bio’s (Nasdaq: GOSS) $212 Million Private PlacementJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Neoleukin Therapeutics’ (Nasdaq: NLTX) Proposed Merger with NeurogeneJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Pardes Biosciences’ (Nasdaq: PRDS) Proposed Acquisition by MediPacific, Inc.July 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Caribou Biosciences’ (Nasdaq: CRBU) $125 Million Follow-On OfferingJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Bicycle Therapeutics’ (Nasdaq: BCYC) $200.0 Million Follow-On OfferingJuly 2023
News | Deal AnnouncementSVB Securities Serves as Placement Agent for Morphimmune’s $125 Million Private PlacementJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Axsome Therapeutics’ (Nasdaq: AXSM) $225 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for MoonLake Immunotherapeutics’ (Nasdaq: MLTX) $400 Million Upsized Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Talaris Therapeutics’ (Nasdaq: TALS) Proposed Merger with Tourmaline BioJune 2023
News | NewsSVB Securities’ Management Team Signs Definitive Agreement for Buyout of SVB Securities from SVB Financial Group; Firm to Rebrand as Leerink PartnersJune 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Zentalis Pharmaceuticals’ (Nasdaq: ZNTL) $250 Million Follow-On OfferingJune 2023